Tesamorelin: what the research shows and how Belle prescribes it

What tesamorelin is

Tesamorelin is a synthetic peptide built from the 44 amino acid sequence of human growth hormone releasing hormone, stabilized so it lasts longer in the body. It is not growth hormone. It is a stabilized version of the signal your body already uses to ask the pituitary for growth hormone.

FDA approved tesamorelin in 2010 under the brand name Egrifta to reduce excess abdominal fat in adults with HIV who have lipodystrophy, a pattern of visceral fat accumulation linked to antiretroviral treatment. Using compounded tesamorelin for general body composition is off label and is not FDA approved for that purpose. It is available by prescription only, and a licensed clinician decides whether it is clinically appropriate for you after a medical intake and informed consent. Off label is a common and legal practice in medicine: a licensed provider has judged a use clinically reasonable outside the exact terms of a brand approval.

The tesamorelin Belle prescribes is not the Egrifta brand product. It is prepared to your clinician prescription by a US-licensed compounding pharmacy, under USP sterility standards, with your name on the vial. Compounded medications are not FDA approved finished products. A licensed provider determines eligibility. The trial history applies to the studied agent in the population it was studied in, not to every compounded preparation.

One more label fact belongs up front. Egrifta is not indicated for weight loss management, and the label describes its effect on weight as neutral. Tesamorelin is a body composition medication, not a scale medication.

How it is thought to work

Growth hormone releasing hormone, GHRH, is a signal the hypothalamus sends to the pituitary. Tesamorelin binds the same receptors on pituitary cells and stimulates the synthesis and pulsatile release of your own growth hormone. Pulsatile is the operative word: it arrives in waves, in its natural rhythm.

That is the difference between tesamorelin and injected HGH. HGH adds synthetic growth hormone directly. Tesamorelin works upstream at the pituitary and prompts the gland to do its own work.

Growth hormone is both anabolic and lipolytic: it supports tissue building and fat breakdown, partly through IGF-1, a growth factor made mainly in the liver. In the trials, IGF-1 rose and visceral adipose tissue, the deep fat around the abdominal organs, went down. That is a described mechanism under study, not a promise of any result.

What the research shows

Tesamorelin has one of the deeper human evidence bases among growth hormone secretagogues, and nearly all of it comes from adults with HIV and excess abdominal fat.

What we know

The approval rested on two randomized, double blind, placebo controlled phase 3 trials. In the first, published in the New England Journal of Medicine in 2007, 412 patients were followed for 26 weeks. Visceral adipose tissue on CT scan decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group, and triglycerides improved. A pooled analysis of both trials, 806 patients in all, found the reduction held through 52 weeks in patients who stayed on treatment, subcutaneous fat was preserved, and glucose did not change in a clinically meaningful way. Outcomes vary by individual and are not guaranteed.

The second phase 3 trial added a finding worth knowing before you start: patients who switched from tesamorelin to placebo after six months rapidly lost the visceral fat improvement. Tesamorelin works while you take it, which is a fact about the mechanism, not a flaw in the drug.

What research suggests

Later trials looked at the liver. A 2019 trial in Lancet HIV followed 61 people with HIV and fatty liver disease for 12 months; liver fat fell by a relative 37% compared with placebo, and fasting glucose and HbA1c did not differ between groups. A 2026 meta-analysis of five randomized trials, searching the literature through July 2025, reported reductions in visceral fat, trunk fat, liver fat and waist circumference, an increase in lean body mass, and no significant change in subcutaneous fat or BMI.

Researchers have also studied it in broader groups. A randomized 12 week study of 53 patients with type 2 diabetes, sponsored by the manufacturer, found it did not alter insulin response or glycemic control. In metabolic and healthy aging contexts, the human data is still catching up to the clinical use.

What we do not know yet

Off label use is not the same as approved. The visceral fat effect is well documented where it was studied, and the question your provider weighs is whether the same biology applies to you. For adults without HIV, the evidence is the mechanism, the consistency of the HIV trials, and accumulated prescribing experience, which is different in kind from a controlled trial. The approved label also states that long term cardiovascular safety has not been established and that the effects of prolonged IGF-1 elevation are unknown. Those are the open questions, and they are why this is prescribed with monitoring rather than sold on a shelf.

Dr. Taylor on tesamorelin

Tesamorelin stands out among growth hormone secretagogues for the depth of clinical evidence behind it, which says a lot about its quality. I use it primarily for patients with visceral abdominal fat that has not responded to diet and exercise alone, and the reduction data is consistent across multiple trials. The trade-off is cost: it runs higher than other GHRH analogs. Dr. Patrick Taylor, MD, Chief Medical Officer at Belle

Not a replacement for your GLP-1. A different tool.

People often ask whether tesamorelin competes with their weight loss medication. It does not. GLP-1 medications such as tirzepatide and semaglutide act on appetite and blood sugar, and reducing overall weight is their core effect. Tesamorelin prompts your own growth hormone, was studied specifically for deep belly fat, and does not act primarily on appetite.

Because the pathways differ, the two are often considered together under one clinician. Many Belle patients ask about tesamorelin precisely because they are already on tirzepatide or semaglutide, the scale has moved, and the middle has not. It needs a provider, because both medications touch blood sugar, and your clinician reviews tesamorelin alongside every medication you take before prescribing anything.

Who explores it, and who should wait

The most common reason a patient asks about tesamorelin is visceral abdominal fat that has not moved with diet and exercise. That is the application closest to what was studied. Patients also explore it for liver fat, where trial evidence is earlier and smaller, and in healthy aging contexts, where the evidence is mechanism and clinical experience rather than trials. If your only goal is weight on the scale, tesamorelin is not the tool for that goal, and a provider can help you tell the two goals apart.

Who should talk to a provider first

• Active cancer, or a history of cancer that is not fully treated and stable
• Certain pituitary conditions, including pituitary surgery, a pituitary tumor, head irradiation or head trauma
• Pregnancy, planning a pregnancy, or breastfeeding
• Diabetes, prediabetes or any blood sugar concern
• Current use of a GLP-1 or any other medication that affects blood sugar
• A known allergy to tesamorelin or to any ingredient in the preparation
• Recovery from major surgery, serious trauma or acute critical illness

Several of these appear on the approved label as reasons not to prescribe it. Tell your Belle clinician about your full medical history and all medications, including any GLP-1.

Side effects and what your provider monitors

The side effect profile comes from 740 patients treated in the Egrifta trials. The most commonly reported reactions were injection site reactions, fluid related effects (joint pain, limb pain, swelling in the hands and feet, carpal tunnel symptoms), hypersensitivity reactions such as rash or hives, and elevated blood sugar. Fluid related effects come from growth hormone itself and were transient or resolved when treatment stopped.

Two things get monitored, and both follow from the mechanism. The first is blood sugar: growth hormone can reduce insulin sensitivity, and in the approval trials 5% of patients on tesamorelin developed an elevated HbA1c compared with 1% on placebo, so your provider checks glucose before you start and periodically after. The second is IGF-1, which the label says to monitor because the effects of prolonged elevation are unknown. This is not a reason to avoid the medication. It is a reason to have a provider tracking your labs, adjusting as needed, and prepared to stop if something does not look right.

How it is taken

Tesamorelin is given as a small subcutaneous injection at home. Your kit includes step-by-step instructions, and nurse support is available if you want a hand getting started.

Belle prescribes it in a 10-week cycle: medication for eight weeks, followed by a two-week reset that is part of the prescribed protocol. Dosing is not one-size-fits-all. Your provider sets your dose and schedule after your medical intake and adjusts it as your labs come back.

Where the real risk is

For most people considering tesamorelin, the largest risk is not the molecule. It is the vial.

Tesamorelin is widely sold online by vendors whose labels read for research use only. That label is the legal line that lets a vendor sell a chemical without the oversight that applies to medicine. Nobody is verifying identity, purity or sterility on your behalf, and nobody is responsible for what is in the vial. For a peptide whose approved label spells out what to monitor, that absence of supervision is the whole risk.

Pharmacy grade product, prepared by a licensed compounding pharmacy and prescribed through a licensed provider, is a fundamentally different proposition.

How Belle prescribes tesamorelin

Belle offers tesamorelin as a prescription compounded peptide. It begins with a short online screening reviewed by a licensed clinician, who looks at your health history, your goals and any current medications, then builds a protocol around you or tells you tesamorelin is not the right fit. If it is prescribed, a US-licensed compounding pharmacy prepares it to your prescription and ships it to you. A prescription is never guaranteed. That uncertainty is a feature of doing this responsibly, not a flaw in the process.

Belle also prescribes BPC-157, GHK-Cu and MOTS-c as compounded peptides, each after its own provider review.

Many patients report the first noticeable change as a shift in waist measurement rather than in scale weight. In the trials, visceral fat was measured at 26 weeks, and the reduction was typically maintained at 52 weeks in those who continued. Timelines and outcomes vary by individual, and your provider will monitor your progress and adjust your protocol as needed.

Nothing here is medical advice. Decisions about your own care belong with a licensed provider who knows your history.